2977| Volume 381, SUPPLEMENT , 1064-1065, October 15, 2017

Rituximub for neuromyelitis optica relapses: RIN-1 Study

      Background: Neuromyelitis optica (NMO) is a disorder distinct from multiple sclerosis, and is characterized by the presence of anti-aquaporin4 (AQP4) antibody. Rituximab (RTX), which is a monoclonal antibody against CD-20, is recommended as immunotherapy in guidelines, however, the rationale is based on the results of observational or single-arm studies.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect